Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

New gene modification enhances CAR-T cell effectiveness against cancer

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying a specific gene improves the ability of immune cells to combat cancer for an extended period, potentially reducing the chance of cancer recurring.

7 Feb 2025

New findings could make off-the-shelf CAR T cell therapy a reality

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient's own immune T cells and engineering them to recognize specific targets on the surface of the cancer cell.

31 Jan 2025

Pomalidomide shows promise in enhancing immune responses in myeloma

A new editorial was published in Oncoscience's Volume 12 on January 14, 2025, titled "Pomalidomide improved immune profiles in myeloma."

23 Jan 2025

Novel materials show promise in treating multiple myeloma bone lesions

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

15 Jan 2025

Menarini Group signs licensing deal with Insilico for promising cancer treatment

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.

10 Jan 2025

Study uncovers how cancer builds molecular bridges to evade the immune system

"Build your enemy a golden bridge to retreat across" is a piece of advice offered by Sun Tzu in his ancient military treatise, The Art of War.

23 Dec 2024

Scientists create blood test to enhance cancer treatment effectiveness

Scientists from RMIT University and the Doherty Institute have developed a new blood test that could screen cancer patients to help make their treatment safer and more effective.

16 Dec 2024

A new era of targeted therapy with antibody–drug conjugates

TBC

From Sino Biological Inc. 16 Dec 2024

Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM).

10 Dec 2024

Interactive atlas unveils immune changes in multiple myeloma

Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health issues.

14 Nov 2024

Stand Up To Cancer partners with Johnson & Johnson to explore new treatment for AL amyloidosis

Stand Up To Cancer (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a combination of two types of targeted therapies, teclistamab and daratumumab, to treat a rare disease called AL amyloidosis.

12 Nov 2024

VANCE trial marks milestone in t cell therapy for solid tumors

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell therapy.

11 Nov 2024

MD Anderson launches new institute for advancing cell therapy

The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will build upon longstanding MD Anderson clinical and research expertise to lead the world in developing and advancing impactful cell therapies for patients in need.

8 Nov 2024

UCLA and Parker Institute renew alliance to advance cancer immunotherapy

UCLA and the Parker Institute for Cancer Immunotherapy (PICI) have renewed their alliance to advance research in cancer immunotherapy and accelerate the development of curative treatments for the most difficult-to-treat cancers.

16 Oct 2024

Clonal competition assays reveal tumor cell resistance mechanisms

All cells within the same cancer are not the same. They all have genetic errors that turn them into tumor cells, but these errors are not identical.

8 Oct 2024

Epigenetic testing opens new doors for multiple myeloma treatment

Multiple myeloma is a type of blood cancer that appears mainly after the age of sixty. Its incidence, therefore, increases with the aging of the population.

7 Oct 2024

Excess body weight at first cancer diagnosis increases risk of second cancer

Adults with excess body weight at their first cancer diagnosis face a higher risk of developing a second primary cancer, particularly those related to obesity, according to a recent study. The research emphasizes the need for survivorship guidelines targeting weight management.

22 Sep 2024

Multiple myeloma drug shows efficacy in treating rare bleeding disorder

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder.

19 Sep 2024

Cancer drug shows promise for treating rare bleeding disorder

A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in 5,000 people worldwide. The trial, led by Keith McCrae, M.D., of Cleveland Clinic and supported by the National Institutes of Health, was stopped early because of these successful findings, and has been published in the New England Journal of Medicine.

19 Sep 2024

Cancer patients face increased risk of long-term mental health problems

People diagnosed with cancer are at a greater risk of mental health problems even five years after their diagnosis, according to a large-scale study of data from UK GP patient records.

17 Sep 2024